Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Follicular lymphomas of germinal center (B- or T-cell) origin

Written2017-09Antonino Carbone, Annunziata Gloghini
Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC); Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; annunziata.gloghini@istitutotumori.mi.it (AG)

Abstract Follicular lymphomas of germinal center (B- or T-cell) origin include follicular lymphoma (FL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and angioimmunoblastic T-cell lymphoma (AITL).Other lymphomas of presumed follicular origin comprise mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) (Fig. 1). In this article we describe the clinical, pathological and genetic features of follicular lymhomas of germinal center (B- or T-cell) origin.

Keywords Follicular lymphoma; nodular lymphocyte predominant Hodgkin lymphoma ; Angioimmunoblastic T-cell lymphoma

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9690/3 Follicular lymphoma; Paediatric follicular lymphoma
ICD-Morpho 9659/3 Nodular lymphocyte predominant Hodgkin lymphoma
ICD-Morpho 9705/3 Angioimmunoblastic T-cell lymphoma
Atlas_Id 1781
Note Germinal center (GC)-derived lymphomas include follicular lymphoma (FL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and angioimmunoblastic T-cell lymphoma (AITL).

Clinics and Pathology

Disease Follicular lymphomas of germinal center (GC) (B- or T-cell) origin include follicular lymphoma (FL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and angioimmunoblastic T-cell lymphoma (AITL) (Fig. 1).Other lymphomas of presumed follicular origin that comprise mantle cell lymphoma (MCL) andmarginal zone lymphoma (MZL) (Fig. 1) are not herein described. Within the microenvironment of all the follicular lymphomas of GC origin, tumour cells show a topographical and functional relationship with follicular dendritic cells (FDC), and reactive lymphoid and stromal cells (Carbone et al., 2009). The 2008 "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" has addressed the problem of early events in the evolution of lymphoid neoplasia (Campo et al., 2011). Examples of early lymphoma subtypes have been recognized for GC-derived lymphomas and include in situ follicular neoplasia/early FL (Campo et al., 2011, Carbone and Santoro, 2011; Swerdlow et al., 2016), early NLPHL (Carbone and Gloghini, 2012) and early AITL (Carbone and Gloghini, 2014B; Swerdlow et al., 2016).
 
Figure 1. Schematic figure of a lymphoid follicle with its "zones" and the related lymphomas. Lymphomas are placed on the follicular zones according to the location of the putative normal counterpart of the tumor cells. GC-derived lymphomas include both B-cell (Follicular lymphoma [FL], nodular lymphocyte predominant Hodgkin lymphoma [NLPHL]) and T-cell (angioimmunoblastic T-cell lymphoma [AITL]) lymphomas.
Pathology Follicular lymphomas of germinal center B-cell origin.
  • Follicular lymphomas (FL). FLs are derived from GC B cells and maintain the gene expression programme of this stage of differentiation. Histology of FL may be indolent with small cells (centrocytes) or aggressive with larger cells (centroblasts). Unlike normal GC B cells, FLs express BCL2, as a result of the characteristic t(14;18) translocation, together with CD20, CD10 and BCL6.
    In in situ follicular neoplasia the neoplastic cells are localized "in the place" that is occupied by the normal counterpart of the tumour cell, without invasion of surrounding structures (Carbone and Santoro, 2011; Carbone and Gloghini, 2014 A). The abnormal follicles involved by in situ follicular neoplasia have monotonous-appearing GCs surrounded by well-preserved mantle zones. The intrafollicular BCL2 positive GC B cells are located within the meshwork of the CD23+ FDC and coexpress CD10, BCL6 and CD20 and are CD3 negative. The proliferation index rate, as assessed by Ki67, is low. The FDC meshwork usually form a well-developed "spherical" dendritic meshwork with a sharp outline highlighting well-preserved mantle zone. Other patterns that can be seen include contracted/distorted /disintegrated FDC meshworks.
    As compared with in situ follicular neoplasia, the follicles involved by overt FL usually have thinner mantle zones and higher proliferation index rate. However, they have a similar FDC pattern with a well-developed round spherical meshwork.
  • Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Tumour cells are derived from antigen-selected mutating GC B cells, as supported by the expression of BCL6 and CD40, the gene expression profile, the presence of CD4+ and PD1+ T cells surrounding the tumour cells and the presence of a follicular dendritic cell meshwork within the tumour nodules. The so-called NLPHL is a B-cell lymphoma, with a typical antigen profile (Carbone and Gloghini, 2017) (Fig. 2) and an indolent clinical behavior (Carbone et al., 2013). Interestingly, pathologic and molecular studies have shown similarities between NLPHL and T-cell or histiocyte-rich large B-cell lymphoma (THCRLBCL) (Boudová et al, 2003; Brune et al., 2008).
    Other features of NLPHL are reported in the specific article/section of the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
    Follicular lymphomas of germinal center T-cell origin.
    AITL. AITL is a peripheral T-cell lymphoma characterized by a prominent proliferation of high endothelial venules. In early lymph-node involvement by AITL, the neoplastic T cells preferentially occupy the B-cell follicles sometimes mimicking a FL of B-cell origin (Carbone and Gloghini, 2014 B). AITL tumour cells show the phenotype of normal follicular helper T cells. For the designation of AITL, the neoplastic cells should express at least 2 or 3 TFH-related antigens, including CD279/PD1, CD10, BCL6, CXCL13, ICOS, SAP, and CCR5 (reviewed in Swerdlow et al, 2016). Typically, the tumour cells of AITL also express CD3 and CD4. The CD4+ tumour cells represent a minority of the neoplastic cell population, their detection being facilitated by the co-expression of CD10. Neoplastic CD4+ T cells of AITL are admixed with B cells, eosinophils and plasma cells.
  •  
    Figure 2. Phenotypic profile of lymphocyte predominant (LP) tumour cells. Abbreviations. GC, germinal center; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; EBV, Epstein Barr virus.
    Evolution Progression and transformation
    FL is the most common subtype of indolent lymphomas. It is characterized by relapses and remissions, usually controlled by Rituximab. On clinical progression, whether FL histology remains indolent or has become aggressive is an important issue: the relevant salvage therapy is selected based on histology, and a watchful waiting strategy can be adopted if the histology remains indolent (Tomita, 2017). It has been reported that 30-40% of FL cases transform into an aggressive lymphoma (tFL) with a poor prognosis (Bouska et al., 2017). An analysis of lymphoma cell specimens at histological transformation has identified multiple transformation-associated abnormalities, such as MYC upregulation, TP53 mutation and changes in the tumour microenvironment (Kahl and Yang, 2016). Transformation to aggressive lymphoma is a critical event in the clinical course of patients affected by FL. Yet, it is a challenge to reliably predict transformation at the time of diagnosis. However, we are currently lacking a prognostic index that would specifically address transformation rather than disease progression or overall survival (Kridel et al., 2017).
    Regarding NLPHL, clinic and pathologic observations have demonstrated that it may evolve to a completely diffuse T-cell-rich proliferation resembling a THCRLBCL. The 2016 revision of WHO classification has recommended the designation of these cases as THCRLBCL-like transformation of NLPHL (Swerdlow et al., 2016).
    Clinical features of AITL are reported in the specific article/section of the Atlas of Genetics and Cytogenetics in Oncology and Haematology.

    Genetics

    The genes most frequently mutated in tFL include KMT2D (MLL2), CREBBP, EZH2, BCL2 and MEF2B. Many recurrently mutated genes are involved in epigenetic regulation, the Janus-activated kinase-signal transducer and activator of transcription (STAT) or the nuclear factor-kb pathways, immune surveillance and cell cycle regulation (Bouska et al., 2017).
    Table 1 shows genetic alterations of clinical value in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), of the GC B-cell origin type).
    Table 1.
    Disease subtypeGenes

    Normal function

    Technology used to detect

    Genotype-directed therapy

    FL/GCB DLBCL

    BCL2

    Antiapoptotic

    FISH

    Venetoclax

     

    KMT2D/MLL2

    H3K4 methyltransferase

    Sequencing

     

     

    CREBBP

    Histone acetyltransferase

    Sequencing

    Trials of HDAC inhibitors

     

    EP300

    Histone acetyltransferase

    Sequencing

     

     

    EZH2

    H3K27 methyltransferase

    Sequencing

    Trials of EZH2 inhibitors

     

    MEF2B

    Transcription factor

    Sequencing

     


    Modified and adapted from Taylor et al., (2017).
    Genetic features of NLPHL are reported in the specific article/section of the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
    Recurrent genetic abnormalities in AITL include TET2, IDH2, DNMT3A, RHOA, and CD28 mutations, as well as gene fusions such as ITK/SYK or CTLA4 / CD28 (Leclaire Alirkilicarslan et al., 2017). All these abnormalities have a role in the process of lymphomagenesis and may represent the target of tailored therapies (reviewed in Swerlow et al., 2016).

    Bibliography

    Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma
    Boudová L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S, Diehl V, Müller-Hermelink HK, Rüdiger T
    Blood 2003 Nov 15;102(10):3753-8
    PMID 12881319
     
    Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma
    Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, Ludvigsen M, Fu K, Weisenburger DD, Greiner TC, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Wu CI, Staudt LM, D'Amore F, McKeithan TW, Chan WC
    Leukemia 2017 Jan;31(1):83-91
    PMID 27389057
     
    Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis
    Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von Heydebreck A, Metzler D, Bräuninger A, Hansmann ML, Küppers R
    J Exp Med 2008 Sep 29;205(10):2251-68
    PMID 18794340
     
    The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES
    Blood 2011 May 12;117(19):5019-32
    PMID 21300984
     
    Hodgkin lymphoma classification: Are we at a crossroads? Cancer
    Carbone A, Gloghini A
    2017 Oct 1;123(19):3654-3655 doi: 10
    PMID 28621881
     
    Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome
    Carbone A, Spina M, Gloghini A, Ponzoni M, Doglioni C, Tirelli U
    Am J Hematol 2013 Feb;88(2):161-2
    PMID 23349009
     
    Follicular lymphoma: evolving therapeutic strategies
    Kahl BS, Yang DT
    Blood 2016 Apr 28;127(17):2055-63
    PMID 26989204
     
    Can histologic transformation of follicular lymphoma be predicted and prevented? Blood
    Kridel R, Sehn LH, Gascoyne RD
    2017 Jul 20;130(3):258-266 doi: 10
    PMID 28408460
     
    Expression of TFH Markers and Detection of RHOA p
    Leclaire Alirkilicarslan A, Dupuy A, Pujals A, Parrens M, Vergier B, Robson A, Delfau-Larue MH, Ingen-Housz-Oro S, Chosidow O, Haioun C, Beylot-Barry M, Merlio JP, Copie-Bergman C, Gaulard P, Ortonne N
    G17V and IDH2 p R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas
    PMID 28945625
     
    The 2016 revision of the World Health Organization classification of lymphoid neoplasms
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES
    Blood 2016 May 19;127(20):2375-90
    PMID 26980727
     
    Diagnosis and classification of hematologic malignancies on the basis of genetics
    Taylor J, Xiao W, Abdel-Wahab O
    Blood 2017 Jul 27;130(4):410-423
    PMID 28600336
     

    Citation

    This paper should be referenced as such :
    Carbone A, Gloghini A
    Follicular lymphomas of germinal center (B- or T-cell) origin;
    Atlas Genet Cytogenet Oncol Haematol. in press
    On line version : http://AtlasGeneticsOncology.org/Anomalies/FollLymphGerminCentID1781.html


    External links

    arrayMapMorph ( 9690/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
    arrayMapMorph ( 9659/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
    arrayMapMorph ( 9705/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Disease databaseFollicular lymphomas of germinal center (B- or T-cell) origin
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed
    All articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Tue Nov 21 15:08:32 CET 2017


    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.